A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 84,34 (-3,49%). A mediana é € 89,33 (+2,22%).
| Comprar |
11 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline
Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Mais em de.investing.com
Kiniksa Pharmaceuticals reaches record high at $64.85
Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Mais em de.investing.com
Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%
Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Mais em de.investing.com
Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance
Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Mais em de.investing.com
Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket
Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 252,47 mi | 63,82% |
| Ganho bruto | 134,53 mi | 62,32% |
| Ganho líquido | 41,8 mi | 166,08% |
| EBITDA | 52,57 mi | 124,01% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 6,86 bi |
Número de ações | 78,57 mi |
Máximo/mínimo de 52 semanas | € 90,06 - € 33,57 |
| Dividendos | Não |
Beta | 0,08 |
PER (PE Ratio) | 67,36 |
PEG (PEG Ratio) | 0,35 |
P/VC (PB Ratio) | 10,61 |
P/V (PS Ratio) | 8,00 |
Perfil da empresa
A Kiniksa Pharmaceuticals, Ltd., uma empresa biofarmacêutica, dedica-se à descoberta, aquisição, desenvolvimento e comercialização de medicamentos terapêuticos para doentes com doenças debilitantes e necessidades médicas não satisfeitas significativas a nível mundial. Os seus candidatos a medicamento incluem o ARCALYST, uma interleucina-1alfa e interleucina-1beta, para o tratamento da pericardite recorrente, que é uma doença cardiovascular inflamatória; o Mavrilimumab, um inibidor de anticorpo monoclonal que concluiu os ensaios clínicos de Fase II para o tratamento da arterite de células gigantes; o Vixarelimab, um anticorpo monoclonal, que se encontra em ensaio clínico de Fase 2a para o tratamento do prurigo nodular, uma doença inflamatória crónica da pele; e o KPL-404, um inibidor de anticorpo monoclonal da interação CD40-CD154, um sinal coestimulador das células T crítico para a maturação das células B, a mudança de classe das imunoglobulinas e a resposta imunitária do tipo 1. A Kiniksa Pharmaceuticals, Ltd. foi constituída em 2015 e tem sede em Hamilton, Bermudas.
| Nome | KINIKSA A BE-,000273235 |
| CEO | Sanj K. Patel |
| Sede | London,
gl Bermudas |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 25/05/2018 |
| Colaboradores | 366 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | KNSA |